Despite drug’s Phase 2 failure in ulcerative colitis, BMS keeps blockbuster hopes

Healthcare

Bristol Myers Squibb drug deucravacitinib missed the main and secondary goals of a Phase 2 study in ulcerative colitis. Despite the clinical trial failure, the drug previously posted positive Phase 3 results in plaque psoriasis and BMS still projects the molecule will become a blockbuster seller in multiple autoimmune conditions.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.